Deaths counts for influenza, pneumonia, and COVID-19 reported to NCHS by week ending date, by state and HHS region, and age group.

This file contains the provisional percent of total deaths by week for COVID-19, Influenza, and Respiratory Syncytial Virus for deaths occurring among residents in the United States. Provisional data are based on non-final counts of deaths based on the flow of mortality data in National Vital Statistics System.

Motivation

Why did I create this dataset? This is my first time creating a notebook in Kaggle and I am interested in learning more about COVID-19 and how different countries are affected by it and why. It might be useful to compare different metrics between different countries. And I also wanted to participate in a challenge, and I've decided to join the COVID-19 datasets challenge. While looking through the projects, I noticed https://www.kaggle.com/koryto/countryinfo and it inspired me to start this project.

Method

My approach is to scour the Internet and Kaggle looking for country data that can potentially have an impact on how the COVID-19 pandemic spreads. In the end, I ended up with the following for each country:

• Monthly temperature and precipitation from Worldbank
• Latitude and longitude
• Population, density, gender and age
• Airport traffic from Worldbank
• COVID-19 date of first case and number of cases and deaths as of March 26, 2020
• 2009 H1N1 flu pandemic cases and deaths obtained from Wikipedia
• Property affordability index and Health care index from Numbeo
• Number of hospital beds and ICU beds from Wikipedia
• Flu and pneumonia death rate from Worldlifeexpectancy.com (Age Adjusted Death Rate Estimates: 2017)
• School closures due to COVID-19
• Number of COVID-19 tests done
• Number of COVID-19 genetic strains
• US Social Distancing Policies from COVID19StatePolicy’s SocialDistancing repository on GitHub
• DHL Global Connectedness Index 2018 (People Breadth scores)
• Datasets have been merged by country name whenever possible. I needed to rename some countries by hand, e.g. US to United Sates, etc. but it's possible that I might have missed some. See the output file covid19_merged.csv for the merged result.

See covid19_data - data_sources.csv for data source details.

Notebook: https://www.kaggle.com/bitsnpieces/covid19-data

Caveats

Since I did not personally collect each datapoint, and because each datasource is different with different objectives, collected at different times, measured in different ways, any inferences from this dataset will need further investigation.

Other interesting sources of information

• IMF Policy Tracker
• nCov strain analysis across the globe!
• Google Mobility Report
• Oxford government response tracker
• Impact on aviation
• Impact on restaurants
• Harvard
• Tableau datahub
• Unemployment outlook from ILO

Acknowledgements

I want to acknowledge the authors of the datasets that made their data publicly available which has made this project possible. Banner image is by Brian.

I hope that the community finds this dataset useful. Feel free to recommend other datasets that you think will be useful / relevant! Thanks for looking.

This dataset represents preliminary estimates of cumulative U.S. COVID-19 disease burden for the 2024-2025 period, including illnesses, outpatient visits, hospitalizations, and deaths. The weekly COVID-19-associated burden estimates are preliminary and based on continuously collected surveillance data from patients hospitalized with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The data come from the Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET), a surveillance platform that captures data from hospitals that serve about 10% of the U.S. population. Each week CDC estimates a range (i.e., lower estimate and an upper estimate) of COVID-19 -associated burden that have occurred since October 1, 2024.

Note: Data are preliminary and subject to change as more data become available. Rates for recent COVID-19-associated hospital admissions are subject to reporting delays; as new data are received each week, previous rates are updated accordingly.

References

1. Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369. https://doi.org/10.1371/journal.pone.0118369 
2. Rolfes, MA, Foppa, IM, Garg, S, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respi Viruses. 2018; 12: 132– 137. https://doi.org/10.1111/irv.12486
3. Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine. 2018;36(48):7331-7337. doi:10.1016/j.vaccine.2018.10.026 
4. Collier SA, Deng L, Adam EA, Benedict KM, Beshearse EM, Blackstock AJ, Bruce BB, Derado G, Edens C, Fullerton KE, Gargano JW, Geissler AL, Hall AJ, Havelaar AH, Hill VR, Hoekstra RM, Reddy SC, Scallan E, Stokes EK, Yoder JS, Beach MJ. Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States. Emerg Infect Dis. 2021 Jan;27(1):140-149. doi: 10.3201/eid2701.190676. PMID: 33350905; PMCID: PMC7774540.
5. Reed C, Kim IK, Singleton JA,  et al. Estimated influenza illnesses and hospitalizations averted by vaccination–United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1151-4. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a2.htm 
6. Reed C, Angulo FJ, Swerdlow DL, et al. Estimates of the Prevalence of Pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15(12):2004-2007. https://dx.doi.org/10.3201/eid1512.091413  
7. Devine O, Pham H, Gunnels B, et al. Extrapolating Sentinel Surveillance Information to Estimate National COVID-19 Hospital Admission Rates: A Bayesian Modeling Approach. Influenza and Other Respiratory Viruses. https://onlinelibrary.wiley.com/doi/10.1111/irv.70026. Volume18, Issue10. October 2024.
8. https://www.cdc.gov/covid/php/covid-net/index.html">COVID-NET | COVID-19 | CDC 
9. https://www.cdc.gov/covid/hcp/clinical-care/systematic-review-process.html 
10. https://academic.oup.com/pnasnexus/article/1/3/pgac079/6604394?login=false">Excess natural-cause deaths in California by cause and setting: March 2020 through February 2021 | PNAS Nexus | Oxford Academic (oup.com)
11. Kruschke, J. K. 2011. Doing Bayesian data analysis: a tutorial with R and BUGS. Elsevier, Amsterdam, Section 3.3.5.

Provisional counts of the number of death occurrences in England and Wales due to coronavirus (COVID-19) and influenza and pneumonia, by age, sex and place of death.

This dataset is a per-state amalgamation of demographic, public health and other relevant predictors for COVID-19.

Deaths, Infections and Tests by State

The COVID Tracking Project: https://covidtracking.com/data/api

Used positive, death and totalTestResults from the API for, respectively, Infected, Deaths and Tested in this dataset. Please read the documentation of the API for more context on those columns

Predictor Data and Sources

Population (2020)

Density is people per meter squared https://worldpopulationreview.com/states/

ICU Beds and Age 60+

https://khn.org/news/as-coronavirus-spreads-widely-millions-of-older-americans-live-in-counties-with-no-icu-beds/

GDP

https://worldpopulationreview.com/states/gdp-by-state/

Income per capita (2018)

https://worldpopulationreview.com/states/per-capita-income-by-state/

Gini

https://en.wikipedia.org/wiki/List_of_U.S._states_by_Gini_coefficient

Unemployment (2020)

Rates from Feb 2020 and are percentage of labor force
https://www.bls.gov/web/laus/laumstrk.htm

Sex (2017)

Ratio is Male / Female
https://www.kff.org/other/state-indicator/distribution-by-gender/

Smoking Percentage (2020)

https://worldpopulationreview.com/states/smoking-rates-by-state/

Influenza and Pneumonia Death Rate (2018)

Death rate per 100,000 people
https://www.cdc.gov/nchs/pressroom/sosmap/flu_pneumonia_mortality/flu_pneumonia.htm

Chronic Lower Respiratory Disease Death Rate (2018)

Death rate per 100,000 people
https://www.cdc.gov/nchs/pressroom/sosmap/lung_disease_mortality/lung_disease.htm

Active Physicians (2019)

https://www.kff.org/other/state-indicator/total-active-physicians/

Hospitals (2018)

https://www.kff.org/other/state-indicator/total-hospitals

Health spending per capita

Includes spending for all health care services and products by state of residence. Hospital spending is included and reflects the total net revenue. Costs such as insurance, administration, research, and construction expenses are not included.
https://www.kff.org/other/state-indicator/avg-annual-growth-per-capita/

Pollution (2019)

Pollution: Average exposure of the general public to particulate matter of 2.5 microns or less (PM2.5) measured in micrograms per cubic meter (3-year estimate)
https://www.americashealthrankings.org/explore/annual/measure/air/state/ALL

Medium and Large Airports

For each state, number of medium and large airports https://en.wikipedia.org/wiki/List_of_the_busiest_airports_in_the_United_States

Temperature (2019)

Note that FL was incorrect in the table, but is corrected in the Hottest States paragraph
https://worldpopulationreview.com/states/average-temperatures-by-state/
District of Columbia temperature computed as the average of Maryland and Virginia

Urbanization (2010)

Urbanization as a percentage of the population https://www.icip.iastate.edu/tables/population/urban-pct-states

Age Groups (2018)

https://www.kff.org/other/state-indicator/distribution-by-age/

School Closure Dates

Schools that haven't closed are marked NaN https://www.edweek.org/ew/section/multimedia/map-coronavirus-and-school-closures.html

Note that some datasets above did not contain data for District of Columbia, this missing data was found via Google searches manually entered.

Data is from the California Department of Public Health (CDPH) Respiratory Virus Weekly Report.

The report is updated each Friday.

Laboratory surveillance data: California laboratories report SARS-CoV-2 test results to CDPH through electronic laboratory reporting. Los Angeles County SARS-CoV-2 lab data has a 7-day reporting lag. Test positivity is calculated using SARS-CoV-2 lab tests that has a specimen collection date reported during a given week.

Laboratory surveillance for influenza, respiratory syncytial virus (RSV), and other respiratory viruses (parainfluenza types 1-4, human metapneumovirus, non-SARS-CoV-2 coronaviruses, adenovirus, enterovirus/rhinovirus) involves the use of data from clinical sentinel laboratories (hospital, academic or private) located throughout California. Specimens for testing are collected from patients in healthcare settings and do not reflect all testing for influenza, respiratory syncytial virus, and other respiratory viruses in California. These laboratories report the number of laboratory-confirmed influenza, respiratory syncytial virus, and other respiratory virus detections and isolations, and the total number of specimens tested by virus type on a weekly basis.

Test positivity for a given week is calculated by dividing the number of positive COVID-19, influenza, RSV, or other respiratory virus results by the total number of specimens tested for that virus. Weekly laboratory surveillance data are defined as Sunday through Saturday.

Hospitalization data: Data on COVID-19 and influenza hospital admissions are from Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network (NHSN) Hospitalization dataset. The requirement to report COVID-19 and influenza-associated hospitalizations was effective November 1, 2024. CDPH pulls NHSN data from the CDC on the Wednesday prior to the publication of the report. Results may differ depending on which day data are pulled. Admission rates are calculated using population estimates from the P-3: Complete State and County Projections Dataset provided by the State of California Department of Finance (https://dof.ca.gov/forecasting/demographics/projections/). Reported weekly admission rates for the entire season use the population estimates for the year the season started. For more information on NHSN data including the protocol and data collection information, see the CDC NHSN webpage (https://www.cdc.gov/nhsn/index.html).

CDPH collaborates with Northern California Kaiser Permanente (NCKP) to monitor trends in RSV admissions. The percentage of RSV admissions is calculated by dividing the number of RSV-related admissions by the total number of admissions during the same period. Admissions for pregnancy, labor and delivery, birth, and outpatient procedures are not included in total number of admissions. These admissions serve as a proxy for RSV activity and do not necessarily represent laboratory confirmed hospitalizations for RSV infections; NCKP members are not representative of all Californians.

Weekly hospitalization data are defined as Sunday through Saturday.

Death certificate data: CDPH receives weekly year-to-date dynamic data on deaths occurring in California from the CDPH Center for Health Statistics and Informatics. These data are limited to deaths occurring among California residents and are analyzed to identify influenza, respiratory syncytial virus, and COVID-19-coded deaths. These deaths are not necessarily laboratory-confirmed and are an underestimate of all influenza, respiratory syncytial virus, and COVID-19-associated deaths in California. Weekly death data are defined as Sunday through Saturday.

Wastewater data: This dataset represents statewide weekly SARS-CoV-2 wastewater summary values. SARS-CoV-2 wastewater concentrations from all sites in California are combined into a single, statewide, unit-less summary value for each week, using a method for data transformation and aggregation developed by the CDC National Wastewater Surveillance System (NWSS). Please see the CDC NWSS data methods page for a description of how these summary values are calculated. Weekly wastewater data are defined as Sunday through Saturday.

Dataset on deaths involving COVID-19, pneumonia, and influenza reported to NCHS by race, age, and jurisdiction of occurrence.

The Chicago Department of Public Health (CDPH) receives weekly deidentified provisional death certificate data for all deaths that occur in Chicago, which can include both Chicago and non-Chicago residents from the Illinois Department of Public Health (IDPH) Illinois Vital Records System (IVRS). CDPH scans for keywords to identify deaths with COVID-19, influenza, or respiratory syncytial virus (RSV) listed as an immediate cause of death, contributing factor, or other significant condition. The percentage of all reported deaths that are attributed to COVID-19, influenza, or RSV is calculated as the number of deaths for each respective disease divided by the number of deaths from all causes, multiplied by 100. This dataset reflects death certificates that have been submitted to IVRS at the time of transmission to CDPH each week – data from previous weeks are not updated with any new submissions to IVRS. As such, estimates in this dataset may differ from those reported through other sources. This dataset can be used to understand trends in COVID-19, influenza, and RSV mortality in Chicago but does not reflect official death statistics. Source: Provisional deaths from the Illinois Department of Public Health Illinois Vital Records System.

Context

Dataset aims to facilitate a state by state comparison of potential risk factors that may heighten Covid 19 transmission rates or deaths. It includes state by state estimates of: covid 19 positives/deaths, flu/pneumonia deaths, major city population densities, available hospital resources, high risk health condition prevalance, population over 60, means of work transportation rates, housing characteristics (ie number of large apartment complexes/seniors living alone), and industry information.

Content

The Data Includes:

1) Covid 19 Outcome Stats:

Covid_Death : Covid Deaths by State

Covid_Positive : Covid Positive Tests by State

2) US Major City Population Density by State: CBSA_Major_City_max_weighted_density

3) KFF Estimates of Total Hospital Beds by State:

Kaiser_Total_Hospital_Beds

4) 2018 Season Flu and Pneumonia Death Stats:

FLUVIEW_TOTAL_PNEUMONIA_DEATHS_Season_2018

FLUVIEW_TOTAL_INFLUENZA_DEATHS_Season_2018

5)US Total Rates of Flu Hospitalization by Underlying Condition:

Fluview_US_FLU_Hospitalization_Rate_....

6) State by State BRFSS Prevalance Rates of Conditions Associated with Higher Flu Hospitalization Rates

BRFSS_Diabetes_Prevalance BRFSS_Asthma_Prevalance BRFSS_COPD_Prevalance
BRFSS_Obesity BMI Prevalance BRFSS_Other_Cancer_Prevalance BRFSS_Kidney_Disease_Prevalance BRFSS_Obesity BMI Prevalance BRFSS_2017_High_Cholestoral_Prevalance BRFSS_2017_High_Blood_Pressure_Prevalance Census_Population_Over_60

7)State by state breakdown of Means of Work Transpotation:

COMMUTE_Census_Worker_Public_Transportation_Rate

8) State by state breakdown of Housing Characteristics

9) State by State breakdown of Industry Information

Acknowledgements

Links to data sources:

https://worldpopulationreview.com/states/

https://covidtracking.com/data/

https://gis.cdc.gov/GRASP/Fluview/FluHospRates.html https://www.kff.org/health-costs/issue-brief/state-data-and-policy-actions-to-address-coronavirus/#stateleveldata

https://data.census.gov/cedsci/table?q=United%20States&tid=ACSDP1Y2018.DP05&hidePreview=true&vintage=2018&layer=VT_2018_040_00_PY_D1&cid=S0103_C01_001E

Census Tables: ACSST1Y2018.S1811 ACSST1Y2018.S0102 ACSST1Y2018.S2403 ACSST1Y2018.S2501 ACSST1Y2018.S2504

https://www.census.gov/library/visualizations/2012/dec/c2010sr-01-density.html

https://gis.cdc.gov/grasp/fluview/mortality.html

Inspiration

I hope to show the existence of correlations that warrant a deeper county by county analysis to identify areas of increased risk requiring increased resource allocation or increased attention to preventative measures.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

Most cost-effective option depending on country income level, influenza, and COVID prevalence among patients with severe COVID-like illness.

This dataset represents preliminary estimates of cumulative U.S. RSV –associated disease burden estimates for the 2024-2025 season, including outpatient visits, hospitalizations, and deaths. Real-time estimates are preliminary and based on continuously collected surveillance data from patients hospitalized with laboratory-confirmed respiratory syncytial virus (RSV) infections. The data come from the Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET), a surveillance platform that captures data from hospitals that serve about 8% of the U.S. population. Each week CDC estimates a range (i.e., lower estimate and an upper estimate) of RSV-associated disease burden estimates that have occurred since October 1, 2024.

Note: Data are preliminary and subject to change as more data become available. Rates for recent RSV-associated hospital admissions are subject to reporting delays; as new data are received each week, previous rates are updated accordingly.

Note: Preliminary burden estimates are not inclusive of data from all RSV-NET sites. Due to model limitations, sites with small sample sizes can impact estimates in unpredictable ways and are excluded for the benefit of model stability. CDC is working to address model limitations and include data from all sites in final burden estimates.

References

1. Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369. https://doi.org/10.1371/journal.pone.0118369 
2. Rolfes, MA, Foppa, IM, Garg, S, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respi Viruses. 2018; 12: 132– 137. https://doi.org/10.1111/irv.12486
3. Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine. 2018;36(48):7331-7337. doi:10.1016/j.vaccine.2018.10.026 
4. Collier SA, Deng L, Adam EA, Benedict KM, Beshearse EM, Blackstock AJ, Bruce BB, Derado G, Edens C, Fullerton KE, Gargano JW, Geissler AL, Hall AJ, Havelaar AH, Hill VR, Hoekstra RM, Reddy SC, Scallan E, Stokes EK, Yoder JS, Beach MJ. Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States. Emerg Infect Dis. 2021 Jan;27(1):140-149. doi: 10.3201/eid2701.190676. PMID: 33350905; PMCID: PMC7774540.
5. Reed C, Kim IK, Singleton JA,  et al. Estimated influenza illnesses and hospitalizations averted by vaccination–United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1151-4. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a2.htm 
6. Reed C, Angulo FJ, Swerdlow DL, et al. Estimates of the Prevalence of Pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15(12):2004-2007. https://dx.doi.org/10.3201/eid1512.091413  
7. Devine O, Pham H, Gunnels B, et al. Extrapolating Sentinel Surveillance Information to Estimate National COVID-19 Hospital Admission Rates: A Bayesian Modeling Approach. Influenza and Other Respiratory Viruses. https://onlinelibrary.wiley.com/doi/10.1111/irv.70026. Volume18, Issue10. October 2024.
8. https://www.cdc.gov/covid/php/covid-net/index.html">COVID-NET | COVID-19 | CDC 
9. https://www.cdc.gov/covid/hcp/clinical-care/systematic-review-process.html 
10. https://academic.oup.com/pnasnexus/article/1/3/pgac079/6604394?login=false">Excess natural-cause deaths in California by cause and setting: March 2020 through February 2021 | PNAS Nexus | Oxford Academic (oup.com)
11. Kruschke, J. K. 2011. Doing Bayesian data analysis: a tutorial with R and BUGS. Elsevier, Amsterdam, Section 3.3.5.

Method

The dataset contains several confirmed COVID-19 cases, number of deaths, and death rate in six regions. The objective of the study is to compare the number of confirmed cases in Africa to other regions.

Death rate = Total number of deaths from COVID-19 divided by the Total Number of infected patients.

The study provides evidence for the country-level in six regions by the World Health Organisation's classification.

Findings

Based on the descriptive data provided above, we conclude that the lack of tourism is one of the key reasons why COVID-19 reported cases are low in Africa compared to other regions. We also justified this claim by providing evidence from the economic freedom index, which indicates that the vast majority of African countries recorded a low index for a business environment. On the other hand, we conclude that the death rate is higher in the African region compared to other regions. This points to issues concerning health-care expenditure, low capacity for testing for COVID-19, and poor infrastructure in the region.

Apart from COVID-19, there are significant pre-existing diseases, namely; Malaria, Flu, HIV/AIDS, and Ebola in the continent. This study, therefore, invites the leaders to invest massively in the health-care system, infrastructure, and human capital in order to provide a sustainable environment for today and future generations. Lastly, policy uncertainty has been a major issue in determining a sustainable development goal on the continent. This uncertainty has differentiated Africa to other regions in terms of stepping up in the time of global crisis.

All-cause, COVID-19, and non-COVID-19 ASDR for ages 25+ by state and time period.

Background: Although coinfection with influenza in COVID-19 patients has drawn considerable attention, it is still not completely understood whether simultaneously infected with these two viruses influences disease severity. We therefore aimed to estimate the impact of coinfected with SARS-CoV-2 and influenza on the disease outcomes compared with the single infection of SARS-CoV-2.Materials and Methods: We searched the PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure Database (CNKI) to identify relevant articles up to July 9, 2021. Studies that assessed the effect of SARS-CoV-2 and influenza coinfection on disease outcomes or those with sufficient data to calculate risk factors were included. Risk effects were pooled using fixed or random effects model.Results: We ultimately identified 12 studies with 9,498 patients to evaluate the risk effects of SARS-CoV-2 and influenza coinfection on disease severity. Results indicated that coinfection was not significantly associated with mortality (OR = 0.85, 95%CI: 0.51, 1.43; p = 0.55, I2 = 76.00%). However, mortality was found significantly decreased in the studies from China (OR = 0.51, 95%CI: 0.39, 0.68; I2 = 26.50%), while significantly increased outside China (OR = 1.56, 95%CI: 1.12, 2.19; I2 = 1.00%). Moreover, a lower risk for critical outcomes was detected among coinfection patients (OR = 0.64, 95%CI: 0.43, 0.97; p = 0.04, I2 = 0.00%). Additionally, coinfection patients presented different laboratory indexes compared with the single SARS-CoV-2 infection, including lymphocyte counts and APTT.Conclusion: Our study revealed that coinfection with SARS-CoV-2 and influenza had no effect on overall mortality. However, risk for critical outcomes was lower in coinfection patients and different associations were detected in the studies from different regions and specific laboratory indexes. Further studies on influenza strains and the order of infection were warranted. Systematic testing for influenza coinfection in COVID-19 patients and influenza vaccination should be recommended.

Data is from the California Department of Public Health (CDPH) Respiratory Virus Weekly Report. The report is updated each Friday. Laboratory surveillance data: California laboratories report SARS-CoV-2 test results to CDPH through electronic laboratory reporting. Los Angeles County SARS-CoV-2 lab data has a 7-day reporting lag. Test positivity is calculated using SARS-CoV-2 lab tests that has a specimen collection date reported during a given week. Laboratory surveillance for influenza, respiratory syncytial virus (RSV), and other respiratory viruses (parainfluenza types 1-4, human metapneumovirus, non-SARS-CoV-2 coronaviruses, adenovirus, enterovirus/rhinovirus) involves the use of data from clinical sentinel laboratories (hospital, academic or private) located throughout California. Specimens for testing are collected from patients in healthcare settings and do not reflect all testing for influenza, respiratory syncytial virus, and other respiratory viruses in California. These laboratories report the number of laboratory-confirmed influenza, respiratory syncytial virus, and other respiratory virus detections and isolations, and the total number of specimens tested by virus type on a weekly basis. Test positivity for a given week is calculated by dividing the number of positive COVID-19, influenza, RSV, or other respiratory virus results by the total number of specimens tested for that virus. Weekly laboratory surveillance data are defined as Sunday through Saturday. Hospitalization data: Data on COVID-19 and influenza hospital admissions are from Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network (NHSN) Hospitalization dataset. The requirement to report COVID-19 and influenza-associated hospitalizations was effective November 1, 2024. CDPH pulls NHSN data from the CDC on the Wednesday prior to the publication of the report. Results may differ depending on which day data are pulled. Admission rates are calculated using population estimates from the P-3: Complete State and County Projections Dataset provided by the State of California Department of Finance (https://dof.ca.gov/forecasting/demographics/projections/). Reported weekly admission rates for the entire season use the population estimates for the year the season started. For more information on NHSN data including the protocol and data collection information, see the CDC NHSN webpage (https://www.cdc.gov/nhsn/index.html). CDPH collaborates with Northern California Kaiser Permanente (NCKP) to monitor trends in RSV admissions. The percentage of RSV admissions is calculated by dividing the number of RSV-related admissions by the total number of admissions during the same period. Admissions for pregnancy, labor and delivery, birth, and outpatient procedures are not included in total number of admissions. These admissions serve as a proxy for RSV activity and do not necessarily represent laboratory confirmed hospitalizations for RSV infections; NCKP members are not representative of all Californians. Weekly hospitalization data are defined as Sunday through Saturday. Death certificate data: CDPH receives weekly year-to-date dynamic data on deaths occurring in California from the CDPH Center for Health Statistics and Informatics. These data are limited to deaths occurring among California residents and are analyzed to identify influenza, respiratory syncytial virus, and COVID-19-coded deaths. These deaths are not necessarily laboratory-confirmed and are an underestimate of all influenza, respiratory syncytial virus, and COVID-19-associated deaths in California. Weekly death data are defined as Sunday through Saturday. Wastewater data: This dataset represents statewide weekly SARS-CoV-2 wastewater summary values. SARS-CoV-2 wastewater concentrations from all sites in California are combined into a single, statewide, unit-less summary value for each week, using a method for data transformation and aggregation developed by the CDC National Wastewater Surveillance System (NWSS). Please see the CDC NWSS data methods page for a description of how these summary values are calculated. Weekly wastewater data are defined as Sunday through Saturday.

Context

• Severe acute respiratory syndrome (SARS) is a viral respiratory disease of zoonotic origin caused by the SARS coronavirus (SARS-CoV).
• Between November 2002 and July 2003, an outbreak of SARS in southern China caused an eventual
• 8,098 cases, resulting in 774 deaths reported in
• 17 countries (9.6% fatality rate), with the majority of cases in mainland China and Hong Kong.
• No cases of SARS have been reported worldwide since 2004.
• In late 2017, Chinese scientists traced the virus through the intermediary of civets to cave-dwelling horseshoe bats in Yunnan province.
• More information https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome

Content

• sars_2003_complete_dataset_clean.csv - The file contains day by day no. from March to July 2003 across the world.
• summary_data_clean.csv - Final no.s from across the world

Acknowledgements / Data Source

https://www.who.int/csr/sars/country/en/

Collection methodology

https://github.com/imdevskp/sars-2003-outbreak-data-webscraping-code

Cover Photo

Photo from CDC website https://www.cdc.gov/dotw/sars/index.html#

Similar Datasets

• COVID-19 - https://www.kaggle.com/imdevskp/corona-virus-report
• MERS - https://www.kaggle.com/imdevskp/mers-outbreak-dataset-20122019
• Ebola Western Africa 2014 Outbreak - https://www.kaggle.com/imdevskp/ebola-outbreak-20142016-complete-dataset
• H1N1 | Swine Flu 2009 Pandemic Dataset - https://www.kaggle.com/imdevskp/h1n1-swine-flu-2009-pandemic-dataset
• SARS 2003 Pandemic - https://www.kaggle.com/imdevskp/sars-outbreak-2003-complete-dataset
• HIV AIDS - https://www.kaggle.com/imdevskp/hiv-aids-dataset

Background: Long-term care facilities had the highest rate of COVID-19 deaths in Canada; thus, it was essential to understand the effectiveness of vaccines and the risk factors for outbreaks in the elderly residents of long-term care and retirement homes. Aims of the CITF-funded study: This study aimed to 1) understand the association between outbreaks and features of long-term care and retirement homes; 2) determine the recurrence rate of outbreaks in homes that have been previously exposed; 3) describe residents’ immune response to infection and vaccination; and 4) estimate vaccine effectiveness in residents. Methods: This cohort study recruited residents from participating long-term care and retirement home across Ontario through invitations from research coordinators. Study visits occurred at participants’ first dose and second dose of the COVID-19 vaccine, and then 3 weeks, 3 months, 6 months, 9, and 12 months post- second dose. For those who got a third dose, follow up was done 3 weeks, 3 months, and 6 months after their third dose. Staff, essential visitors, and resident participants were followed up every week or per visit for saliva surveillance active COVID infection . A DBS whole blood sample was given at enrolment and at each follow up for serology testing. Contributed dataset contents: The datasets include 1261 participants who completed baseline surveys between January 2021 and July 2023. 90% of participants gave one or more blood samples between April 2021 and April 2023 for analysis. A total of 6078 samples were collected. Variables include data in the following areas of information: demographics (date of birth, sex, race-ethnicity, indigeneity), general health (weight and height, smoking, flu vaccination, chronic conditions), SARS-CoV-2 outcomes (positive test results, hospitalizations), SARS-CoV-2 vaccination, and serology (IgA, IgG, and IgM against SARS-CoV-2 receptor-binding domain (RBD) and spike (S) protein).

How did Brazil become a global epicenter of the outbreak? After seeming to ease, is the virus making a comeback?

A world leader in infections and deaths.

Latin America became an epicenter of the coronavirus pandemic in May, driven by Brazil’s ballooning caseload. Ten months after its first known case, Brazil has had more than 7.9 million cases and over 200,000 deaths.

In early June, Brazil began averaging about 1,000 deaths per day from Covid-19, joining the United States — and later India — as the countries with the world’s largest death tolls.

This dataset contains information about COVID-19 in Brazil extracted on the date 16/06/2021. It is the most updated dataset available about Covid in Brazil

Features:

🔍 date: date that the data was collected. format YYYY-MM-DD.
🔍 state: Abbreviation for States. Example: SP
🔍 city: Name of the city (if the value is NaN, they are referring to the State, not the city)
🔍 place_type: Can be City or State
🔍 order_for_place: Number that identifies the registering order for this location. The line that refers to the first log is going to be shown as 1, and the following information will start the count as an index.
🔍 is_last: Show if the line was the last update from that place, can be True or False
🔍 city_ibge_code: IBGE Code from the location
🔍confirmed: Number of confirmed cases.
🔍deaths: Number of deaths.
🔍estimated_population: Estimated population for this city/state in 2020. Data from IBGE
🔍estimated_population_2019: Estimated population for this city/state in 2019. Data from IBGE.
🔍confirmed_per_100k_inhabitants: Number of confirmed cases per 100.000 habitants (based on estimated_population).
🔍death_rate: Death rate (deaths / confirmed cases).

Acknowledgements

This dataset was downloaded from the URL bello. Thanks, Brasil.IO! Their main goal is to make all Brazilian data available to the public DATASET URL: https://brasil.io/dataset/covid19/files/ Cities map file https://geoftp.ibge.gov.br/organizacao_do_territorio/malhas_territoriais/malhas_municipais/municipio_2020/Brasil/BR/

Similar Datasets

COVID-19 - https://www.kaggle.com/rafaelherrero/covid19-brazil-full-cases-17062021 COVID-19 - https://www.kaggle.com/imdevskp/corona-virus-report MERS - https://www.kaggle.com/imdevskp/mers-outbreak-dataset-20122019 Ebola Western Africa 2014 Outbreak - https://www.kaggle.com/imdevskp/ebola-outbreak-20142016-complete-dataset H1N1 | Swine Flu 2009 Pandemic Dataset - https://www.kaggle.com/imdevskp/h1n1-swine-flu-2009-pandemic-dataset SARS 2003 Pandemic - https://www.kaggle.com/imdevskp/sars-outbreak-2003-complete-dataset HIV AIDS - https://www.kaggle.com/imdevskp/hiv-aids-dataset